Oncology Medical News about adrenocortical carcinoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Inhibition of adrenocortical carcinoma cells proliferation by SF-1 inverse agonists
Journal of Clinical Endocrinology and Metabolism, 04/17/09

Doghman M et al. - In a study to investigate the effect of SF-1 inverse agonists of the alkyloxyphenol and isoquinolinone classes on proliferation of human adrenocortical cell lines expressing SF-1 (H295R), in conditions of basal and increased SF-1 expression, or negative for SF-1 expression (SW-13), it was concluded that SF-1 inhibitors may represent a useful tool in the chemotherapy of adrenocortical tumors.

Methods

Proliferation assays, immunoblots, flow cytometric analyses, steroid hormone assays and RT-qPCR were employed.

Results

SF-1 inhibitors of the alkyloxyphenol class displayed a dose-dependent inhibitory effect on both SF-1 – positive and – negative adrenocortical tumor cells, while SF-1 inverse agonists of the isoquinolinone class selectively inhibited cell proliferation elicited by SF-1 overexpression.
These drugs also inhibited stimulated steroid hormone secretion and CYP21 and CYP17 mRNA expression.

<< Previous
Management of brain metastases: the indispensable role of surgery

Next >>
A comparison of radiation treatment plans using IMRT with helical...